Vilin Bio Med logo

Vilin Bio Med financials and balance sheet

NSE: VILINBIOPharmaceuticals & Biotechnology

Last close ₹50.95down ₹1.05 (2.02%)

Share price at the NSE close on 23 Oct 2026. Previous close ₹52.00.

52-week range of traded prices to 23 Oct 2026
₹18.95Low, 16 Dec 2025₹60.95High, 9 Sep 2026
Market cap
₹78 Cr
P/E
40.3
P/B
2.7
Dividend yield
Nonein the last 12 months
ROE
7.5%
Debt to equity
0.01
Volume, NSE
12,000100.0% delivered

4 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Vilin Bio Med annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹42 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue42
  2. Materials and goods−38
  3. Employee costs−0.7
  4. Other expenses−0.7
  5. Operating profit3.2
  6. Depreciation−0.3
  7. Other income0.0
  8. Finance costs−0.1
  9. Profit before tax2.8
  10. Tax−0.9
  11. Net profit1.9

What the company owns

  • Receivables₹16 Cr
  • Plant, investments and other assets₹10 Cr
  • Inventory₹7 Cr
  • Cash and bank₹1 Cr

What pays for it: net worth and liabilities

  • Net worth₹28 Cr
  • Owed to suppliers₹3 Cr
  • Other liabilities₹3 Cr
  • Borrowings₹0 Cr

Profit and loss

Standalone, ₹ crore, years to March.Vilin Bio Med half-yearly results

₹ croreMar 2023Mar 2024Mar 2025Filed 17 MayMar 2026Filed 31 May
Revenue from operations12.315.814.842.3
9.715.014.039.1
Materials and goods bought7.213.013.537.6
Employee costs0.80.80.30.7
Other expenses1.81.20.30.7
Operating profit before depreciation2.60.80.83.2
Operating margin20.9%5.2%5.3%7.6%
Materials, % of revenue58.2%82.3%91.0%89.0%
Employee costs, % of revenue6.3%5.1%2.0%1.8%
Other expenses, % of revenue14.5%7.5%1.7%1.7%
Depreciation and amortisation0.20.10.10.3
Operating profit after depreciation2.40.70.72.9
Other income0.00.30.50.0
Finance costs0.60.80.80.1
One-off items0.00.0––
Profit before tax1.80.20.32.8
0.50.10.10.9
Net profit1.20.20.21.9
Net margin10.1%1.0%1.5%4.6%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2025Filed 17 MayMar 2026Filed 31 May
23.128.4
Share capital14.015.3
Reserves9.113.1
Borrowings2.60.2
4.66.4
0.10.1
Total assets27.734.9
15.27.6
12.627.4
Net debt2.5−1.3
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2023 and Mar 2024, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2025Filed 17 MayMar 2026Filed 31 May
−3.830.70
−3.301.58
−4.55−1.55
Receivables−0.62−7.40
Inventories0.06−2.80
Payables−0.561.92
Other working capital−3.426.74
Tax paid−0.07−0.88
Capital spending1.570.30
Free cash flow−5.410.40
−1.11−0.30
−1.051.01
Dividends paid0.000.00
Shares issued0.003.38
Net change in cash−5.991.41
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2023 and Mar 2024.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2024Mar 2025Filed 17 MayMar 2026Filed 31 May
Earnings per share–₹0.16₹1.37
Diluted earnings per share–₹0.16₹1.37
Book value per share–₹16.53₹18.60
Shareholder yield–0.0%−6.0%
Market cap at the year end (₹ crore)26.528.555.9

Ratios

Standalone, years to March.Vilin Bio Med PE ratio and valuation

RatioMar 2023Mar 2024Mar 2025Filed 17 MayMar 2026Filed 31 May
Revenue growth–28.4%−6.3%185.4%
Operating profit growth–−68.3%−3.7%305.8%
Net profit growth–−86.9%37.5%762.6%
Earnings per share growth–––756.3%
––1.0%7.5%
–––6.5 pts
From the net margin–––2.0 pts
From asset turnover–––4.5 pts
From borrowing–––0.1 pts
Return on capital employed––2.7%10.2%
Cash conversion––−1,713.1%36.2%
Interest cover3.70.90.842.3
Debt to equity––0.110.01
Receivable days––155138
Inventory days––12070
Payable days––3833
Cash conversion cycle, days––237175
Working capital days––259170
Asset turnover––0.531.35
Assets per rupee of net worth––1.201.22
Sales per rupee of plant––11.5314.75
Capital spending to depreciation––15.081.04
No balance sheet is on record for the years to Mar 2023 and Mar 2024, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
6.2%
Cash from operations against operating profit
21.9%
Measure5 years3 years
Revenue growth, yearly rate–50.8%
Profit growth, yearly rate–15.7%
Return on equity, average–4.2%
Return on capital employed, average–6.4%
Operating margin, average9.7%6.0%
Net margin, average4.3%2.4%
Asset turnover, average–0.94
Cash conversion cycle, days, average–206
Interest cover, average11.914.7
Debt to equity, average–0.06

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations0.70
Cash from investing−0.30
Cash from financing1.01
Capital spending0.30
Dividends paid0.00
Shares issued for cash3.38
Borrowings raised0.00
Borrowings repaid2.37

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2023Mar 2024Mar 2025Mar 2026
Receivables growth less revenue growthOur threshold 0 percentage points–––−32.33
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––−115.75
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––2.26
Effective tax ratePublished threshold 17.16 per cent30.1227.8326.9032.11
Tax charged less tax paid, % of profitOur threshold 10 percentage points––4.181.19
A threshold marked as ours has no published figure; it is the line we read the check against.